Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seegene, a biotechnology company, has received international patent protection for a break-through technology able to accelerate the detection of highly personal variations in genetic sequences. These genetic variations can identify an individual's risks for a broad range of disorders, such as Alzheimer's disease and coronary artery diseases, or genetic mutations known to cause various cancers.
Subscribe to our email newsletter
The patent issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene’s proprietary Dual Priming Oligonucleotide (DPO) technology is being applied to haplotyping -the investigation of the genetic background and phenotype structures of complex diseases.
Haplotyping with DPO technology puts in place a sound foundation for solid scientific advances providing a capability to meet pent-up demand for large-scale genetic studies involving thousands of samples, the company said.
According to Seegene, its novel haplotyping process applies the unique primer design technology of its proprietary DPO platform to the multiplex PCR technique widely used in molecular genetic analysis. The method allows the genotyping of six different combinations of Apolipoprotein allele types known to be associated with the risk of developing diseases in a single multiplex PCR. Currently, Seegene is actively seeking targets to apply DPO technology for the performance of detailed genetic analysis.
Jong-Yoon Chun, founder and CEO of Seegene, said: “This novel approach to haplotyping using the Seegene multiplex platform allows biomedical researchers to cross a barrier that to this point has frustrated many – the exploration of observed patterns of genetic sequences that help us understand how the diverse traits reveal themselves as true risks for individuals.”